Ambroxol mitigates renal ischemia/reperfusion-induced cardiac and renal injury via Nrf2/HO-1 activation and TLR4 pathway inhibition
Journal of Pharmacy and Pharmacology · 2025
DOI: 10.1093/jpp/rgaf064 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2025. Verfasst von Hadeer A Fayed und 2 weiteren Autor:innen. Beteiligte Einrichtung: Egyptian Drug Authority, 51 Wizaret el Zeraa St. Al Agouzah, Cairo 12611, Egypt. Hauptthemen laut MEDLINE: Toll-Like Receptor 4, NF-E2-Related Factor 2, Ambroxol, Reperfusion Injury. Die Arbeit nennt 56 Literaturangaben.
Abstract (Originalsprache)
Background
Ambroxol is a mucokinetic drug with antioxidant and anti-inflammatory properties. Renal ischemia/reperfusion (IR) is the cause of acute kidney injury that usually occurs with other comorbidities.
Objectives
To explore ambroxol for repurposing against renal IR-induced cardio-renal injury.
Methods
Sprague–Dawley rats were assigned into: Sham group (Group I), untreated renal IR group (Group II), and ambroxol-pretreated group (Group III). Cardiac injury parameters, histopathology, and oxidative and antioxidant status, plus signaling molecules related to hypoxia, inflammation, mitochondrial dysfunction, and apoptosis were evaluated. Key findings Ambroxol administration significantly (P < .001) improved the IR-deteriorated cardiac biomarkers and histopathology and up-regulated the Nrf2/HO-1 pathway to increase antioxidant capacity. The cardio-renal expression of hypoxia-inducible factor (HIF)-1α was significantly (P < .001) attenuated by ambroxol. Ambroxol also attenuated inflammation by significant (P < .001) down-regulation of TLR4, p38 mitogen-activated protein kinase, nuclear factor kappa B, and nod-like receptor protein 3 expression while decreasing IL-1β and TNF-α secretion. Moreover, ambroxol significantly (P < .001) ameliorated mitochondrial dysfunction and apoptosis. Statistical results revealed positive correlations between the expression of TLR4 and HIF-1 and between TLR4 and dynamin-related protein 1.
Conclusions
Ambroxol’s cardio-renal protecting potential was elicited by inhibiting oxidative stress, inflammation, and mitochondrial dysfunction through activating the Nrf2/HO-1 pathway and inhibiting multiple TLR4-interconnected signaling pathways, thus affording a theoretical base for ambroxol’s clinical use in renal IR-induced injuries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Egyptian Drug Authority, 51 Wizaret el Zeraa St. Al Agouzah, Cairo 12611, Egypt.
- Department of Pharmacology & Toxicology, Faculty of Pharmacy (Girls), Al-Azhar University, Nasr City, Cairo 11651, Egypt.
ORCID-Profile: Azza S Awad
Zitieren
APA
Fayed, H. A., Abdel-Sattar, S. A., & Awad, A. S. (2025). Ambroxol mitigates renal ischemia/reperfusion-induced cardiac and renal injury via Nrf2/HO-1 activation and TLR4 pathway inhibition. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf064
Vancouver
Fayed HA, Abdel-Sattar SA, Awad AS. Ambroxol mitigates renal ischemia/reperfusion-induced cardiac and renal injury via Nrf2/HO-1 activation and TLR4 pathway inhibition. Journal of Pharmacy and Pharmacology. 2025. doi:10.1093/jpp/rgaf064
BibTeX
@article{Fayed2025,
author = {Fayed, Hadeer A and Abdel-Sattar, Somaia A and Awad, Azza S},
title = {Ambroxol mitigates renal ischemia/reperfusion-induced cardiac and renal injury via Nrf2/HO-1 activation and TLR4 pathway inhibition},
journal = {Journal of Pharmacy and Pharmacology},
year = {2025},
doi = {10.1093/jpp/rgaf064}
}
EUVIMED